Amlodipine in Pregnancy: Safety Profile, Risks, and Clinical Guidance

Amlodipine (a dihydropyridine calcium channel blocker) is not a first-line antihypertensive in pregnancy, but may be used when preferred agents are unsuitable.

Pregnancy Category & Evidence

  • FDA: Category C (animal fetal risk, no adequate human studies).
  • ACOG/NHBPEP preferred agents: Methyldopa, labetalol, nifedipine XL. Amlodipine is an alternative.
  • Human data: Registries and cohort studies (thousands of exposures) show no clear pattern of major malformations. Some signal for congenital heart defects (VSD, ASD) and intrauterine growth restriction (IUGR)—confounded by hypertension itself.
  • Placental transfer: Yes (lipophilic).
  • Breastfeeding: Low milk levels; considered compatible (AAP).

Clinical Decision Framework

  • If already on amlodipine + well-controlled → often continued (switching risks destabilization).
  • New onset HTN in pregnancy → start preferred agent (labetalol, nifedipine XL, methyldopa).
  • Severe HTN (≥160/110) → IV labetalol/hydralazine/nifedipine PO; amlodipine not acute.
  • Monitor: BP, fetal growth (serial US), maternal edema, renal function.

Key Counseling Points

  • Uncontrolled hypertension poses greater fetal risk (abruption, IUGR, stillbirth, preeclampsia) than most antihypertensives.
  • Do not stop abruptly—rebound hypertension.
  • Report edema, headache, visual changes, epigastric pain (preeclampsia signs).

Shared decision-making with OB/MFM is essential.

Pregnancy & Health - Related Articles